Related Experiment Video
Updated: Aug 14, 2025

Histological Quantification to Determine Lung Fungal Burden in Experimental Aspergillosis
Published on: March 9, 2018
Mucormycosis and aspergillosis: The deadly duo in COVID-19-a case report
Bijaya Mohanty1, Zeya Ansari1, Anil Prasad2
1Department of Medicine, Jamshedpur, Jharkhand, India.
Abstract:
COVID-19 disease has been associated with fungal infections such as aspergillosis and mucormycosis, especially in diabetic patients who have suffered from a moderately severe form of COVID-19 infection and are treated with steroids. Though there are multiple case reports describing co-infection with mucormycosis during the second wave of the COVID outbreak, the report of a dual fungal infection along with superadded bacterial infection is rare. Here we report a case where the same patient had a fungal storm with aspergillosis and mucormycosis and superadded Klebsiella. She was treated aggressively with antifungal agents, antibiotics, surgical debridement, and other supportive care. She improved and was discharged from the hospital after a long stay. She is being followed up regularly in the outpatient department and doing well.
Insights
This case report details a rare dual fungal infection (aspergillosis and mucormycosis) with a superadded bacterial infection in a COVID-19 patient. Aggressive treatment led to the patient's recovery and successful discharge.
Area of Science:
- Infectious Diseases
- Mycology
- Critical Care Medicine
Background:
- COVID-19 is linked to fungal infections like aspergillosis and mucormycosis, particularly in diabetic patients receiving steroids.
- Co-infections with mucormycosis during COVID-19 outbreaks have been reported, but dual fungal and bacterial infections are uncommon.
Observation:
- A patient with a severe COVID-19 infection developed a rare "fungal storm" involving both aspergillosis and mucormycosis.
- The fungal infection was further complicated by a superadded bacterial infection with Klebsiella.
Findings:
- The patient underwent aggressive treatment including antifungal agents, antibiotics, and surgical debridement.
- Multimodal therapy resulted in the patient's improvement and eventual discharge after a prolonged hospital stay.
Implications:
- This case highlights the potential for complex, polymicrobial infections in severe COVID-19 patients.
- Prompt and aggressive management is crucial for improving outcomes in patients with severe COVID-19 and co-infections.
More Related Videos
15:01Confocal Laser Scanning Microscopy-Based Quantitative Analysis of Aspergillus fumigatus Conidia Distribution in Whole-Mount Optically Cleared Mouse Lung
Published on: September 18, 2021
08:01Detection of Invasive Pulmonary Aspergillosis in Haematological Malignancy Patients by using Lateral-flow Technology
Published on: March 22, 2012
Related Concept Videos
Fungal Group Zygomycota
Fungal Phylum Ascomycota
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Pulmonary Tuberculosis III
The first classification is based on the development of the disease, and it includes the following categories:
COPD: Pathogenesis and Clinical Features
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...